These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23157579)

  • 1. Obesity, dyslipidemia and cholesterol gallstone disease during one year of Antarctic residence.
    Premkumar M; Sable T
    Rural Remote Health; 2012; 12():2186. PubMed ID: 23157579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose acetylsalicylic acid on radiolucent gallstones.
    Tuncer I; Harman M; Mercan R; Oztürk M; Arslan I; Meral C; Türkdoğan MK
    Turk J Gastroenterol; 2003 Jun; 14(2):91-6. PubMed ID: 14614633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss.
    Worobetz LJ; Inglis FG; Shaffer EA
    Am J Gastroenterol; 1993 Oct; 88(10):1705-10. PubMed ID: 8213711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
    Cariati A; Piromalli E
    Expert Opin Pharmacother; 2012 Jun; 13(9):1223-7. PubMed ID: 22607008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for gallstone disease in patients with gallstones having gallstone heredity. A case-control study.
    Tîrziu S; Bel S; Bondor CI; Acalovschi M
    Rom J Intern Med; 2008; 46(3):223-8. PubMed ID: 19366081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallstone disease: Primary and secondary prevention.
    Venneman NG; van Erpecum KJ
    Best Pract Res Clin Gastroenterol; 2006; 20(6):1063-73. PubMed ID: 17127188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of gallstones by ursodeoxycholic acid after cardiac surgery.
    Ai T; Azemoto R; Saisho H
    J Gastroenterol; 2003; 38(11):1071-6. PubMed ID: 14673725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy.
    Venneman NG; Besselink MG; Keulemans YC; Vanberge-Henegouwen GP; Boermeester MA; Broeders IA; Go PM; van Erpecum KJ
    Hepatology; 2006 Jun; 43(6):1276-83. PubMed ID: 16729326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficiency of ursotherapy in cholesterol-associated pathology of the gallbladder].
    Il'chenko AA; Drozhzhina IuV
    Eksp Klin Gastroenterol; 2009; (8):96-101. PubMed ID: 20469685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional approaches to prevention and treatment of gallstones.
    Gaby AR
    Altern Med Rev; 2009 Sep; 14(3):258-67. PubMed ID: 19803550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of biliary dysfunction in the pathogenesis of gallstone disease].
    Il'chenko IA; Deliukina OV
    Eksp Klin Gastroenterol; 2011; (7):70-8. PubMed ID: 22364003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.
    Tomida S; Abei M; Yamaguchi T; Matsuzaki Y; Shoda J; Tanaka N; Osuga T
    Hepatology; 1999 Jul; 30(1):6-13. PubMed ID: 10385632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors of familial gallstone disease: study of 135 pedigrees].
    Qin J; Han TQ; Fei J; Jiang ZY; Zhang Y; Yang SY; Jiang ZH; Cai XX; Huang W; Zhang SD
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(28):1966-9. PubMed ID: 16313772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral dissolution therapy for cholelithiasis: mix and match.
    Phillips RS; Barkin JS
    Am J Gastroenterol; 1990 Nov; 85(11):1532-3. PubMed ID: 2239886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gallstone formation during weight-reduction dieting.
    Liddle RA; Goldstein RB; Saxton J
    Arch Intern Med; 1989 Aug; 149(8):1750-3. PubMed ID: 2669662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dietetic therapy of obesity. Preliminary considerations on the combined therapy with ursodeoxycholic acid in the prevention of cholesterol lithiasis].
    De Filippo E; Ferrieri A; Marra M; Contaldo F
    Minerva Med; 1993 May; 84(5):269-74. PubMed ID: 8316346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease.
    Tsai S; Strouse PJ; Drongowski RA; Islam S; Teitelbaum DH
    J Pediatr Surg; 2005 Jan; 40(1):263-7. PubMed ID: 15868595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic efficacy of ursodeoxycholic acid in persistent gallbladder lithiasis and persistent biliary sludge: preliminary results of a multicenter experience].
    Guma C; Viola L; Apestegui C; Pinchuk L; Groppa J; Michelini J; Martínez B; Bolaños R; Toselli L
    Acta Gastroenterol Latinoam; 1994; 24(4):233-7. PubMed ID: 7701907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects.
    Mazzella G; Cipolla A; Villanova N; Polimeni C; Sipahi A; Parini P; Fusaroli P; Festi D; Roda E
    Ital J Gastroenterol; 1995; 27(8):441-5. PubMed ID: 8775472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.